Tonix Pharmaceuticals Holding Stock Performance
| TNXP Stock | USD 0.19 0.01 5.00% |
On a scale of 0 to 100, Tonix Pharmaceuticals holds a performance score of 4. The entity has a beta of 3.26, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tonix Pharmaceuticals will likely underperform. Please check Tonix Pharmaceuticals' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to make a quick decision on whether Tonix Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Tonix Pharmaceuticals Holding are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Tonix Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:32 | Dividend Date 2019-11-01 | Last Split Date 2024-06-10 |
1 | Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace SymTouch to Treat Migraines | 09/27/2024 |
2 | Tonix Pharmaceuticals announces submission of NDA for non-opioid analgesic | 10/16/2024 |
3 | Can Tonixs Antivirals Boost Military Defense | 10/17/2024 |
4 | Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 | 10/24/2024 |
5 | Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 | 11/01/2024 |
6 | Tonix Pharmaceuticals GAAP EPS of -0.23 beats by 3.65, revenue of 2.82M misses by 0.33M | 11/12/2024 |
7 | Tonix Pharmaceuticals Announces Peer-Reviewed Publication in mSphere Journal Highlighting the Tolerability of Companys Single-Dose Mpox and Smallpox Vaccine Can... | 11/13/2024 |
8 | Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments | 11/14/2024 |
9 | Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology Convergence 2024 Annua... | 11/18/2024 |
10 | Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference | 11/26/2024 |
| Begin Period Cash Flow | 120.5 M |
Tonix |
Tonix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 17.00 in Tonix Pharmaceuticals Holding on September 2, 2024 and sell it today you would earn a total of 2.00 from holding Tonix Pharmaceuticals Holding or generate 11.76% return on investment over 90 days. Tonix Pharmaceuticals Holding is currently generating 0.4125% in daily expected returns and assumes 7.1152% risk (volatility on return distribution) over the 90 days horizon. In different words, 63% of stocks are less volatile than Tonix, and 92% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tonix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tonix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tonix Pharmaceuticals Holding, and traders can use it to determine the average amount a Tonix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.058
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TNXP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.12 actual daily | 63 63% of assets are less volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Tonix Pharmaceuticals is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tonix Pharmaceuticals by adding it to a well-diversified portfolio.
Tonix Pharmaceuticals Fundamentals Growth
Tonix Stock prices reflect investors' perceptions of the future prospects and financial health of Tonix Pharmaceuticals, and Tonix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tonix Stock performance.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (8.31) % | ||||
| Current Valuation | 15.91 M | ||||
| Shares Outstanding | 186.89 M | ||||
| Price To Earning | (0.69) X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 2.85 X | ||||
| Revenue | 7.77 M | ||||
| EBITDA | (114.09 M) | ||||
| Net Income | (116.66 M) | ||||
| Cash And Equivalents | 145.48 M | ||||
| Cash Per Share | 3.38 X | ||||
| Total Debt | 9.81 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 12.05 X | ||||
| Book Value Per Share | 57.61 X | ||||
| Cash Flow From Operations | (102 M) | ||||
| Earnings Per Share | (80.39) X | ||||
| Market Capitalization | 35.45 M | ||||
| Total Asset | 154.46 M | ||||
| Retained Earnings | (600.66 M) | ||||
| Working Capital | 28.88 M | ||||
| Current Asset | 46.36 M | ||||
| Current Liabilities | 6.65 M | ||||
About Tonix Pharmaceuticals Performance
Assessing Tonix Pharmaceuticals' fundamental ratios provides investors with valuable insights into Tonix Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Tonix Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.1 K | 1.1 K | |
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.87) | (0.92) | |
| Return On Assets | (0.76) | (0.79) | |
| Return On Equity | (1.11) | (1.16) |
Things to note about Tonix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tonix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tonix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tonix Pharmaceuticals had very high historical volatility over the last 90 days | |
| Tonix Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Tonix Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.77 M. Net Loss for the year was (116.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tonix Pharmaceuticals Holding currently holds about 145.48 M in cash with (102 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tonix Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Tonix Pharmaceuticals to Participate in the NobleCon20 Investor Conference |
- Analyzing Tonix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tonix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tonix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tonix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tonix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tonix Pharmaceuticals' stock. These opinions can provide insight into Tonix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Tonix Stock Analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.